Melanoma antigen preferentially expressed in tumors (300-309)

Melanoma antigen preferentially expressed in tumors (300-309) is a synthetic peptide corresponding to amino acids 300 through 309 of the MAGE-A1 protein, a member of the melanoma-associated antigen family. As a well-characterized epitope derived from a cancer-testis antigen, this peptide is recognized for its immunogenic properties and its restricted expression profile, being predominantly found in various tumor types while largely absent from normal tissues except for the testis. Its unique sequence and tumor-associated nature have made it a valuable tool for researchers investigating antigen processing, immune recognition, and tumor immunology. The peptide is widely utilized in studies aiming to elucidate mechanisms of tumor immune surveillance, antigen presentation, and the development of peptide-based immunological assays.

Epitope mapping: Researchers employ the (300-309) peptide fragment in epitope mapping studies to define the minimal antigenic regions recognized by cytotoxic T lymphocytes (CTLs). By using this defined sequence, scientists can dissect the specificity of T cell responses against melanoma-associated antigens, enabling the identification of immunodominant epitopes and providing insights into the molecular interactions governing tumor antigen recognition.

Immunogenicity assessment: The peptide serves as a critical reagent in the evaluation of T cell immunogenicity, particularly in the context of cancer immunology. By incorporating the MAGE-A1 (300-309) sequence into in vitro assays such as ELISPOT, intracellular cytokine staining, or tetramer-based flow cytometry, investigators can quantitatively assess the frequency, activation status, and functional profile of antigen-specific T cells within patient-derived or experimental samples. This application is essential for understanding the immune repertoire targeting tumor antigens and for monitoring immune responses in preclinical research.

Antigen presentation studies: The defined sequence of the (300-309) peptide makes it an effective probe for studying the mechanisms of major histocompatibility complex (MHC) class I antigen processing and presentation. By loading this peptide onto antigen-presenting cells or using it in cell-based assays, researchers can investigate the efficiency of peptide-MHC binding, the stability of peptide-MHC complexes, and the requirements for effective T cell activation. Such studies inform the design of optimized peptide-based immunogens and contribute to the broader understanding of tumor immune evasion.

Peptide-based assay development: The synthetic nature and well-characterized immunological relevance of the (300-309) fragment support its use in the development and validation of peptide-based immunoassays. It is frequently utilized as a positive control or as a target analyte in cytotoxicity assays, T cell activation tests, or peptide-MHC binding studies. These applications facilitate the standardization and benchmarking of experimental systems in tumor immunology research.

Peptide synthesis and modification studies: The (300-309) sequence is also of interest to peptide chemists and structural biologists exploring modifications that enhance peptide stability, binding affinity, or immunogenicity. By synthesizing analogs or incorporating chemical modifications, researchers can examine structure-activity relationships, optimize peptide design for research use, and evaluate the impact of sequence alterations on biological function. This contributes to the advancement of peptide engineering strategies in the context of cancer antigen research.

1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

2. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

3. TMEM16F and dynamins control expansive plasma membrane reservoirs

4. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

5. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides